Current Report No: 17/2024
Date: 19.08.2024 r.
Legal Basis: Article 17, Section 1 of the MAR Regulation – Confidential Information
The Management of Medicalgorithmics S.A., based in Warsaw “Company”, informs that on August 19, 2024, a resolution was adopted regarding the conversion of registered ordinary Series J shares into bearer ordinary shares “Resolution”. By virtue of the aforementioned Resolution, the Company’s Management, acting on the basis of §5 4 sentence 2 of the Company’s Articles of Association and Article 334 §2 of the Commercial Companies Code, at the request of the Company’s shareholder – Biofund Capital Management LLC “Shareholder”, converted 1,194,331 registered Series J shares with a nominal value of PLN 0.10 each from registered ordinary shares to bearer ordinary shares in the same number: 1,194,331.
Before the conversion, the Series J shares were registered ordinary shares, and after the conversion, they became bearer ordinary shares belonging to the Shareholder. The amount of the Company’s share capital after the conversion remains unchanged at PLN 995,276.90. The total number of votes at the Company’s general meeting after the conversion also remains unchanged at 9,952,769.
The Company reminds that in current report No. 55/2022 dated October 1, 2022, it informed that 4,976,384 shares, which were subscribed by Biofund Capital Management LLC, based in Miami _USA_, in accordance with the investment agreement dated October 1, 2022, between the Company and Biofund Capital Management LLC, are to be introduced to stock market trading under the applicable exceptions from the obligation to prepare a prospectus, with the planned date for introducing all these shares to trading set for the end of 2026. Under this procedure, in June 2023, 995,276 bearer ordinary Series I shares of the Company were already admitted to stock market trading, as indicated in current report No. 14/2023 dated June 14, 2023. This conversion of shares at the Shareholder’s request was also carried out in execution of the provisions of this investment agreement, i.e., for the purpose of introducing Series J shares to stock market trading without the obligation to prepare a prospectus, as indicated in current report No. 55/2022 dated October 1, 2022.